TransMedics to Present at the Canaccord 40th Annual Growth Conference
TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplant technology, will present at the Canaccord 40th Annual Growth Conference on August 13, 2020, at 10:00 a.m. EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplant technology, will present at the Canaccord 40th Annual Growth Conference on August 13, 2020, at 10:00 a.m. EDT. This virtual event aims to highlight their innovations in portable organ preservation and assessment, which are critical for improving transplantation outcomes for patients with end-stage heart, lung, and liver failure. A live and archived webcast will be available on their website.
Details
News Market Reaction – TMDX
The recorded move for TMDX in the trading session of this news was +4.07%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANDOVER, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be presenting at the virtual Canaccord 40th Annual Growth Conference. The presentation will take place on Thursday, August 13, 2020 at 10:00 a.m. EDT.
Event: Canaccord 40th Annual Growth Conference
Date: Thursday, August 13, 2020
Time: 10:00 a.m. EDT
A live and archived webcast of the event will be available on the “Investors” section of the TransMedics website at www.transmedics.com.
About TransMedics Group, Inc.
TransMedics is the world’s leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung and liver failure.
Investor Contact:
Brian Johnston
631-807-1986
Investors@transmedics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.